Mylan Extends the EpiPen4School Program!

I was very excited to hear this morning that Mylan Specialty (makers of EpiPen) have decided to extend their EpiPen4School Program another year. For many, there has been a deadline looming over our heads to push the schools to take advantage of this awesome program before the end of the year. Big breath out, relax and dig your heels in to keep pushing forward for the safety of all of our children and school staff, not just those who have allergies.
Why all? Allergic reactions can happen at any time to anyone at any age. Think about how you would feel if you found out your daughter was allergic to a food because she had her initial reaction at school but had no EpiPen prescribed for her. How terrifying would that be? And what else would be more life-changing for students if they had to watch their teacher go into anaphylactic shock because she unknowingly developed a food allergy and was not prepared? For most of us with allergies, we are prepared. We keep our EpiPens with us and we educate the people around us to know what to do if an allergic reaction occurs. But what about those who don't have their EpiPen with them that day? What about the people who wake up just like every other day but their day ends quite tragically just because of a food or a bee sting? We cannot ignore them and we cannot exclude them. Everyone deserves to have a backup plan and I feel that EpiPen4School will be, in the very least, a big part of that answer.

Mylan's press release read " Mylan Specialty L.P., the fully integrated specialty pharmaceutical business of Mylan Inc. (NASDAQ: MYL), today announced it is continuing the EpiPen4Schools™ program. In its first year, more than 20,000 schools across all 50 states participated in the program that offers four free EpiPen or EpiPen Jr® (epinephrine) Auto-Injectors to qualifying schools in the U.S. Qualifications include having a valid prescription.

Over the last year, there has been significant legislative movement across the country to improve access to epinephrine, which should encourage more schools to take advantage of the EpiPen4Schools program. The goal of the program is to help schools have ready access to epinephrine auto-injectors in case a person experiences a life-threatening allergic reaction (anaphylaxis) at school. People are encouraged to visit www.EpiPen4Schools.com for more information.

"Educating the public about anaphylaxis preparedness and working to improve access to treatment continues to be an important focus at Mylan, which is why we are pleased to be able to extend EpiPen4Schools," said Heather Bresch, CEO of Mylan. "We hope all schools that have participated in the past will sign up again, and those that haven't yet enrolled in the EpiPen4Schools program will do so quickly, so that EpiPen Auto-Injectors are in place by the start of the 2013 school year."

I also want to remind everyone to use the $0 copay EpiPen discount plan for personal prescriptions (Click here for the link). Our family took full advantage of this program and I do admit, not having the cost of three EpiPen Twin Paks was a huge relief. I know that they are absolutely necessary to have but back to school costs always add up to more than we are expecting. We also shared information with our local pharmacy Robinhood Family Pharmacy to make it even easier for our community to find out about the program. Make sure you share with your pharmacy and schools as well. Although the information is out there, many people still do not know what it is or how to utilize it. Sharing is caring so educate others to empower them.


I also want to personally thank Mylan Specialty for these programs. Budgeting can be tricky with prescriptions, foods, supplies, anything that an allergic child needs. I am grateful that Mylan is caring enough to understand that those who need their EpiPens also need extra help and support sometimes. Sometimes all we need to hear is "I understand, I can help".

For more information on the EpiPens, please visit their site at https://www.myepipen.com/.



Comments